Zinnat Indications/Uses

Cefuroxime (as axetil) (Zinnat) is an oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms.
It is indicated for the treatment of infections caused by susceptible bacteria. Susceptibility to cefuroxime (as axetil) (Zinnat) will vary with geography and time and local susceptibility data should be consulted where available (see Pharmacology: Pharmacodynamics: Pharmacodynamic effects under Actions).
Indications include: upper respiratory tract infections (for example: ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis); lower respiratory tract infections (for example: pneumonia, acute exacerbations of chronic bronchitis); genito-urinary tract infections (for example: pyelonephritis, cystitis and urethritis); skin and soft tissue infections (for example: furunculosis, pyoderma and impetigo); gonorrhoea, acute uncomplicated gonococcal urethritis, and cervicitis; treatment of early Lyme disease and subsequent prevention of late Lyme disease.
Tablet: Cefuroxime is also available as the sodium salt (ZINACEF) for parenteral administration. This permits the use of sequential therapy with the same antibiotic, when a change from parenteral to oral therapy is clinically indicated.
Where appropriate Cefuroxime (as axetil) (Zinnat) is effective when used following initial parenteral cefuroxime sodium (ZINACEF) in the treatment of pneumonia and acute exacerbations of chronic bronchitis.